Get the Stockscreener App
156.89
0.28%
0.44
After Hours:
156.60
-0.29
-0.18%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $156.89, with a volume of 3.28M.
It is up +0.28% in the last 24 hours and down -7.11% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$156.45
Open:
$156.3
24h Volume:
3.28M
Relative Volume:
1.17
Market Cap:
$243.32B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
47.12
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
-3.10%
1M Performance:
-7.11%
6M Performance:
-25.11%
1Y Performance:
+98.17%
1-Day Range:
$155.78
$157.26
1-Week Range:
$154.53
$162.26
52-Week Range:
$72.89
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
156.89 | 242.64B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,183.16 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
262.37 | 627.42B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.33 | 440.83B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.97 | 335.14B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.97 | 286.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Health Care Down on Growth DoubtsHealth Care Roundup - marketscreener.com
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth - Morningstar
AstraZeneca Halts Phase III Lung Cancer Trial as Drug Falls Short Against Keytruda - finance.biggo.com
AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant - Yahoo Finance UK
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer - biopharmadive.com
UK Shares Start Week Downbeat; AstraZeneca Shares Data from Lung Cancer Trials - Yahoo Finance UK
AstraZeneca stock gains on lung cancer trial news - ad-hoc-news.de
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies - benzinga.com
Market Wrap: EU chip stocks surge on Anthropic's earnings! AstraZeneca halts trials for lung cancer therapy (17.08.2026) - XTB.com
AstraZeneca (AZN) drug delays progression in first-line HER2 lung cancer - Stock Titan
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda - Clinical Trials Arena
AstraZeneca (NYSE: AZN) halts lung trial after survival goals seen unlikely - Stock Titan
Lung cancer trial success puts AstraZeneca (AZN) drug duo in play - Stock Titan
Plato Investment Management Ltd Takes $5.90 Million Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca halts lung cancer trial in fresh pipeline setback - Proactive financial news
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review -- Update - marketscreener.com
FTSE 100 Gains Support From Miners, AstraZeneca And Rolls-Royce - DirectorsTalk Interviews
AstraZeneca Stops Cancer Drug Trial as Success Seen Unlikely - Bloomberg.com
AstraZeneca Halts Lung Cancer Trial for Volrustomig; Reports Positive Data for Tagrisso Combo, Enhertu - Yahoo Finance UK
AstraZeneca halts lung trial as two cancer drugs show positive results - marketscreener.com
AstraZeneca (LSE:AZN) Puts Blue-Chip Stocks Under An Earnings-Quality Spotlight - Kalkine Media
AstraZeneca Reports Positive Results with Lung Cancer Drugs - marketscreener.com
AstraZeneca scraps late-stage lung cancer trial after data setback - Investing.com Nigeria
Why is AstraZeneca stock up today? By Investing.com - Investing.com UK
Triple news for AstraZeneca - marketscreener.com
AstraZeneca reports Phase III survival benefit for Tagrisso–Orpathys lung cancer combination - Yahoo Finance UK
AstraZeneca, Daiichi Sankyo's Enhertu Improves Progression-free Survival in Late-stage Lung Cancer Trial - marketscreener.com
AstraZeneca discontinues lung cancer trial of volrustomig - Investing.com Nigeria
AstraZeneca ends one trial; Telecom Plus backs view - marketscreener.com
AstraZeneca lung cancer drug combination extends survival in trial - Proactive financial news
AstraZeneca discontinues lung cancer trial of volrustomig By Investing.com - Investing.com UK
AstraZeneca’s Tagrisso plus Orpathys extends survival in lung cancer - Investing.com Nigeria
AstraZeneca reports positive Phase III results for Tagrisso-Orpathys lung cancer combination - DirectorsTalk Interviews
AstraZeneca Ends Late-stage Metastatic Non-small Cell Lung Cancer Trial - marketscreener.com
REGAstraZeneca PLCUpdate on eVOLVE-Lung02 Phase III trial - TradingView
Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial - AstraZeneca
Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer - AstraZeneca
S&CO Inc. Takes Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca up significantly this week: Key Trends Investors Should Watch - Kalkine Media
AstraZeneca Joins States Aiming To Block Ill. 340B Drug Law - Law360
AstraZeneca slips Friday, underperforms market - MarketWatch
AstraZeneca stock holds near $157 after earnings beat - AD HOC NEWS
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? - fool.com
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story? - Yahoo Finance
Sarah Ketterer's Top Q2 2026 Move: AstraZeneca PLC at a 3.92% Po - GuruFocus
AstraZeneca stock holds steady as Q2 2026 earnings beat supports outlook - AD HOC NEWS
Wealthcare Advisory Partners LLC Purchases Shares of 12,112 Astrazeneca Plc $AZN - MarketBeat
AstraZeneca (LSE:AZN) Leads a Defensive Test for UK Blue Chips - Kalkine Media
AstraZeneca slips Wednesday, underperforms market - MarketWatch
AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Combo Gets Approval in China - marketscreener.com
Daiichi, AstraZeneca drug Enhertu wins further approval in China - marketscreener.com
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.00%
2.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):